John A. Petros, MD

John  Petros, M.D.Professor of Urology

Associate Chair for Research

Professor of Hematology and Medical Oncology

Professor of Pathology and Labratroy Medicine

Clinical Practice Sites

Atlanta VA Medical Center (Primary)
(404) 728-4120

Emory Univeristy Hospital
(404) 778-5000

Undergraduate Education

AB in Chemistry and Biology
Washington University, St. Louis, MO (1982)

Medical School

Loyola University Stritch School of Medicine, Chicago Illinois (1986)


Washington University, Barnes Hospital, St. Louis Missouri (1986-1987)

Urology Residency

Washington University, Barnes Hospital, St. Louis Missouri (1987-1993)

Board Certification

American Board of Urology (1995)

Clinical and Academic Appointments

Emory University School of Medicine (1993-present)
Atlanta VA Medical Center (1993-present)

Primary Clinical Interests

Prostate Cancer
Kidney Cancer
Bladder Cancer

All Areas of Clinical Interest

bladder cancer/tumors
prostate cancer
renal cancer
testicular cancer

Year Started Practice:


Year Started at Emory:


See full curriculum vitae

About Dr. Petros

Dr. Petros is a Professor of Urology and the Associate Chair of Research at Emory University School of Medicine. Dr. Petros holds secondary academic appointments as Professor of Hematology and Medical Oncology, and Professor of Pathology and Laboratory Medicine at Emory.

Dr. Petros received an Artium Baccalaureatus (AB) Degree from Washington University in St. Louis Missouri majoring in Chemistry and Biology. He attended medical school at Loyola University Stritch School of Medicine, Chicago Illinois. He completed his urology residency training at Washington University, Barnes Hospital, St. Louis Missouri. In 1993, Dr. Petros joined the Department of Urology at Emory University as an academic faculty urologist and scientist. Dr. Petros is a Diplomate of the American Board of Urology (1995). Dr. Petros has been both a practicing surgical urologist and the principal investigator of a basic science laboratory for the entire time he has been at Emory (1993-present).  While taking care of patients every week he has maintained continuous extramural funding for his laboratory for over 20 years.

Dr. Petros is most well know for pioneering the field of mitochondrial DNA (mtDNA) mutations in prostate cancer having been the first to show that inherited mutations of this genome result in increased likelihood of developing prostate cancer.  Major contributions to this field have included showing that mtDNA mutations exert their cancer promoting influence by altering the production of cellular reactive oxygen and reactive nitrogen species, which in turn activate a cascade of tumor-promoting molecular events.  The ultimate clinical translation of these findings may be the development of novel therapies targeting these molecules.  This research also holds the promise of patient-individualized (personalized) medicine in that individuals could be identified that have inherited these gene mutations and selected for more intensive screening and early treatment. Dr. Petros found that mutations in the mtDNA are much more common in African Americans with prostate cancer than Caucasian Americans with prostate cancer.  This may be responsible for some of the health disparities in this disease where African American men are at higher risk for developing and/or dying of prostate cancer. In addition, Dr. Petros is conducting research designed to develop a new diagnostic blood or urine test for kidney cancer.  

Dr. Petros is married to his wife of 31 years (Teresa) a practicing pediatrician and together they are raising 5 daughters.  Dr. Petros is active in faith-based (Catholic) medical missions including missions to Ghana Africa, El Salvador and Mexico.  Dr. Petros serves on the Board of Directors for the Associated Credit Union (ACU) in Norcross GA, a $1.3 Billion dollar financial institution.  Dr. Petros also serves on the board of the ACU foundation responsible for local charitable donations. In 2011 Dr. Petros was selected “Alumnus of the Year” by Loyola University Stritch School of Medicine for his work in missions.

Honors & Awards

2011 Alumnus of the Year
Loyola University Stritch School of Medicine

Best Scientific Research Poster, American Urological Association (2010)
"Mitochondrial DNA Mutations Increase with Metastasis in Prostate Cancer"
The 95th American Urological Association Convention, San Francisco, California

Emory University Millipub Club - Single manuscript with at least 1000 citations (2010)
"Measurement of Prostate-specific antigen in serum as a screening test for prostate cancer."
New England Journal of Medicine 324(17): 1156-1161, 1991

Letter of Commendation for Excellence in Clinical Service (2006)
"Excellent Customer Service"

Letter of Commendation for Excellence in Clinical Service (2002)
"Improved Wait Times at the Atlanta VA Medical Center"

Emory University Hospital Clinical Research Center Award (1994)

Clinical Oncology Career Development Award, American Cancer Society (1994)

CaP Cure Research Award (1993)
"Gene Therapy of Prostate Cancer"

First Prize Scientific Research, American Urological Association (1991)
"Effects of digital rectal examination, prostate massage transrectal ultrasonography and needle biopsy of the prostate on serum prostate specific antigen"

Gunnar Memorial Scholarship Nominee (Top 5% of Medical Class) (1985)

Loyola University President's Medallion (1985)

Alpha Omega Alpha (Junior Year) (1984)

Alpha Sigma Nu Jesuit Honor Society (1984)


Issa MM, Al-Qassab UA, Hall J, Ritenour CWM, Petros JA, Sullivan JW. Formalin Disinfection of Biopsy Needle Minimizes the Risk of Sepsis Following Prostate Biopsy. Journal of Urology 2013 May 25 [Epub ahead of print]

Shrewsberry AB, Al-Qassab UA, Goodman M, Petros JA, Sullivan JW, Ritenour CWM, Issa MM. A +20% Adjustment in the CT Measured Ureteral Length is an Accurate Predictor of True Ureteral Length Prior to Ureteral Stent Placement. Journal of Endourology 27(8): 1041-1045, 2013.

Arnold RS, Sun Q, Sun CQ, Richards JC, O’Hearn S, Osunkoya AO, Wallace DC, Petros JA.  An inherited heteroplasmic mutation in mitochondrial gene COI in a patient with prostate cancer alters reactive oxygen, reactive nitrogen and proliferation.  BioMed Research International. 2013:239257, 2013.

Mauzo, S. H., Lee, M., Petros, J., Hunter, S., Chang, C. M., Shu, H. K., ... & Cohen, C. (2012). Immunohistochemical Demonstration of Isocitrate Dehydrogenase 1 (IDH1) Mutation in a Small Subset of Prostatic Carcinomas. Applied Immunohistochemistry & Molecular Morphology

Baldie KG. Al-Qassab UA. Ritenour CW. Issa MM. Osunkoya AO. Petros JA. Pelvic nephroureterectomy for renal cell carcinoma in an ectopic kidney.  Case Reports in Oncological Medicine. 2012:350916, 2012.

Scott TA, Arnold RS, Petros JA.  Mitochondrial cytochrome c oxidase subunit 1 sequence variation in prostate cancer.  Scientifica vol. 2012, Article 701810, 7 pages, 2012. doi:10.6064/2102/701810

Long Q, Johnson BA, Osunkoya AO, Lai YH, Zhou W, Abramovitz M, Xia M, Bouzyk MB, Nam RK, Sugar L, Stanimirovic A, Williams DJ, Leyland-Jones BR, Seth AK, Petros JA, Moreno CS.  Protein-coding and microRNA biomarkers of recurrence of prostate cancer following radical prostatectomy.  American Journal of Pathology. 179(1): 46-54, 2011 Jul

Garnier-Amblard EC, Mays SG, Arrendale RF, Baille MT, Bushnev AS, Culver DG, Evers TJ, Holt JJ, Howard RB, Liebeskind LS, Menaldino DS, Natchus MG, Petros JA, Ramaraju H, Reddy GP, Liotta DC.  Novel synthesis and biological evaluation of enigmols as therapeutic agents for treating prostate cancer.  ACS Med Chem Lett 2: 438-443, 2011.

Abd TT, Goodman M, Hall J, Ritenour CW, Petros JA, Marshall FF, Issa MM.  Comparison of 12-core versus 8-core prostate biopsy: multivariate analysis of large series of US veterans.  Urology. 77(3):521-547, March 2011

Makarova N, Zhao C, Zhang Y, Bhosle S, Suppiah S, Rhea JM, Kozyr N, Arnold RS, Ly H, Molinaro RJ, Parslow TG, Hunter E, Liotta D, Petros J, Blackwell JL.  Antibody response against xenotropic murine leukemia virus-related virus envelope in a murine model.  PLoS ONE 6(4):e18272, 2011

Arnold RS. Makarova NV. Osunkoya AO. Suppiah S. Scott TA. Johnson NA. Bhosle SM. Liotta D. Hunter E. Marshall FF. Ly H. Molinaro RJ. Blackwell JL. Petros JA. XMRV infection in patients with prostate cancer: novel serologic assay and correlation with PCR and FISH. Urology. 75(4):755-61, 2010 Apr.

Bhosle S, Suppiah S, Molinaro R, Liang Y, Arnold R, Diehl W, Makarova N, Blackwell J, Petros JA, Liotta D, Hunter E, Ly H. Evaluation of cellular determinants required for in vitro XMRV entry of human prostate cancer and non-cancerous cells. J Virol.  Apr 21. 2010.

Czarnecka AM, Krawczyk T, Plak K, Klemba A, Zdrozny M, Arnold RS, Kofler B, Golik P, Szybinska A, Lubinski J, Mossakowska M, Bartnik E, Petros JA.  Mitochondrial genotype and breast cancer predisposition.  Oncology Reports. 24(6): 1521-1534, 2010 Dec.

Liu J, Lau SK, Varma VA, Moffitt RA, Caldwell M, Liu T, Young AN, Petros JA, Osunkoya AO, Krogstad T, Leyland-Jones B, Wang MD Nie S.  Molecular mapping of tumor heterogeneity on clinical tissue specimens with multiplexed quantum dots.  Acs Nano 4(5): 2755-2765, 2010 May 25.

Czarnecka AM, Klemba A, Krawczyk T, Zdrozny M, Arnold RS, Bartnik E, Petros JA.  Mitochondrial NADH-dehydrogenase polymorphisms as sporadic breast cancer risk factor.  Oncology Reports. 23(2): 531-535, 2010 Feb.

Czarnecka AM, Krawczyk T, Zdrozny M, Lubinski J, Arnold RS, Kukwa W, Scinska A, Golik P, Bartnik E, Petros JA: Mitochondrial NADH-dehydrogenase subunit 3 (ND3) polymorphism (A10398G) and sporadic breast cancer in Poland. Breast Cancer Res Treat 121(2): 511-518, 2010, Jun.

Arnold RS, Sun CQ, Richards JC, Grigoriev G,  Coleman IM, Nelson PS, Hsieh CL, Lee JK, Xu Z, Rogatko A, Zayzafoon M,  Chung L,  Petros JA. Mitochondrial DNA Mutation Stimulates Prostate Cancer Growth in Bone Stromal Environment. Prostate. 69(1):1-11, 2009 Jan 1.

Ray A, Zuhlke K, Levin A, Douglas JA, Cooney KA, Petros JA. Sequence variation in the mitochondrial gene cytochrome c oxidase subunit I and prostate cancer in African American men. Prostate 69(9): 956-960, 2009 Jun 15.

Moses KA, Abd TT, Goodman M, Hsiao W, Hall JA, Marshall FF, Petros JA, Issa MM.  Increased low density lipoprotein and increased likelihood of positive prostate biopsy in black Americans,  J Urol 182(5): 2219-25, Nov 2009

Dong XY. Rodriguez C. Guo P. Sun X. Talbot JT. Zhou W. Petros J. Li Q. Vessella RL. Kibel AS. Stevens VL. Calle EE. Dong JT. SnoRNA U50 is a candidate tumor-suppressor gene at 6q14.3 with a mutation associated with clinically significant prostate cancer. Human Molecular Genetics. 17(7):1031-42, 2008 Apr 1.

Chen C. Sun X. Guo P. Dong XY. Sethi P. Zhou W. Zhou Z. Petros JA. Frierson HF Jr. Vessella RL. Atfi A. Dong JT. Ubiquitin E3 ligase WWP1 as an oncogenic factor in human prostate cancer. Oncogene. 26(16):2386-94, 2007 Apr 5.

Xing Y. Chaudry Q. Shen C. Kong KY. Zhau HE. Chung LW. Petros JA. O'Regan RM. Yezhelyev MV. Simons JW. Wang MD. Nie S. Bioconjugated quantum dots for multiplexed and quantitative immunohistochemistry. Nature Protocols. 2(5):1152-65, 2007.

Lee D. Khaja S. Velasquez-Castano JC. Dasari M. Sun C. Petros JA. Taylor WR. Murthy N. In vivo imaging of hydrogen peroxide with chemiluminescent nanoparticles.  Nature Materials. 6(10):765-9, 2007 Oct.

Arnold RS. He J. Remo A. Ritsick D. Yin-Goen Q. Lambeth JD. Datta MW. Young AN. Petros JA. Nox1 expression determines cellular reactive oxygen and modulates c-fos-induced growth factor, interleukin-8, and Cav-1. American Journal of Pathology. 171(6):2021-32, 2007 Dec.

Booker LM. Habermacher GM. Jessie BC. Sun QC. Baumann AK. Amin M. Lim SD. Fernandez-Golarz C. Lyles RH. Brown MD. Marshall FF. Petros JA. North American white mitochondrial haplogroups in prostate and renal cancer. Journal of Urology. 175(2):468-73, 2006 Feb.

Yin-Goen Q. Dale J. Yang WL. Phan J. Moffitt R. Petros JA. Datta MW. Amin MB. Wang MD. Young AN. Advances in molecular classification of renal neoplasms. Histology & Histopathology. 21(3):325-39, 2006 Mar.

Sung SY. Kubo H. Shigemura K. Arnold RS. Logani S. Wang R. Konaka H. Nakagawa M. Mousses S. Amin M. Anderson C. Johnstone P. Petros JA. Marshall FF. Zhau HE. Chung LW. Oxidative Stress Induces ADAM9 Protein Expression in Human Prostate Cancer Cells. Cancer Research. 66(19):9519-26, 2006 Oct 1.

Issa MM. Zasada W. Ward K. Hall JA. Petros JA. Ritenour CW. Goodman M. Kleinbaum D. Mandel J. Marshall FF. The value of digital rectal examination as a predictor of prostate cancer diagnosis among United States Veterans referred for prostate biopsy. Cancer Detection & Prevention. 30(3):269-75, 2006

Sun CQ, Arnold R, Fernandez-Golarz C, Parrish AB, Almekinder T, He J. Ho SM, Svoboda P. Pohl J, Marshall FF, Petros JA. Human {beta}-Defensin-1, a Potential Chromosome 8p Tumor Suppressor: Control of Transcription and Induction of Apoptosis in Renal Cell Carcinoma. Cancer Research. 66(17): 8542-9, 2006 Sep 1.

Johnstone PA. Ward KC. Goodman M. Assikis V. Petros JA. Radical prostatectomy for clinical T4 prostate cancer. Cancer. 106(12):2603-9, 2006 Jun 15

Young AN. Dale J. Yin-Goen Q. Harris WB. Petros JA. Datta MW. Wang MD. Marshall FF. Amin MB. Current trends in molecular classification of adult renal tumors.  Urology. 67(5):873-80, 2006 May

Ramachandran S. Liu P. Young AN. Yin-Goen Q. Lim SD. Laycock N. Amin MB. Carney JK. Marshall FF. Petros JA. Moreno CS. Loss of HOXC6 expression induces apoptosis in prostate cancer cells. Oncogene. 24(1):188-98, 2005 Jan 6.

—  Lim SD. Sun C. Lambeth JD. Marshall F. Amin M. Chung L. Petros JA. Arnold RS. Increased Nox1 and hydrogen peroxide in prostate cancer. Prostate. 62(2):200-7, 2005 Feb 1.

—  Petros JA, Baumann AK, Ruiz-Pesini E, Amin MB, Sun CQ, Hall J, Lim SD, Issa MM, Flanders WD, Hosseini SH, Marshall FF, Wallace DC.  MtDNA mutations increase tumorigenicity in prostate cancer.  Proceedings of the National Academy of Sciences USA 102 (2):719-724, 2005 Jan 18.

—  Gao X, Yang L, Petros JA, Marshall FF, Simons JW, Nie S.  In vivo molecular and cellular imaging with quantum dots.  Current Opinions in Biotchnology.  16:1-10, 2005.

—  Sun X. Frierson HF. Chen C. Li C. Ran Q. Otto KB. Cantarel BM. Vessella RL. Gao AC. Petros JA. Miura Y. Simons JW. Dong JT. Frequent somatic mutations of the transcription factor ATBF1 in human prostate cancer. Nature Genetics. 37(4):407-12, 2005 Apr.

—  St Luce S. Ninan AC. Hall JA. Kimberl IJ. Petros JA. Issa MM. Role of transrectal ultrasonography in diagnosis and treatment of retained Foley catheter. Urology. 65(5):1001, 2005 May.

—  Schuetz AN. Yin-Goen Q. Amin MB. Moreno CS. Cohen C. Hornsby CD. Yang WL. Petros JA. Issa MM. Pattaras JG. Ogan K. Marshall FF. Young AN. Molecular classification of renal tumors by gene expression profiling. Journal of Molecular Diagnostics. 7(2):206-18, 2005 May.

—  Ninan AC. St Luce S. Kimberl IJ. Petros JA. Issa MM.  Endoscopic enucleation of leiomyoma of the bladder. Urologia Internationalis. 75(1):8-9, 2005.

—  Issa MM. Lendvay TS. Bouet R. Young MR. Petros JA. Marshall FF. Epididymal sparing bilateral simple orchiectomy with epididymoplasty: preservation of esthetics and body image. Journal of Urology. 174(3):893-7, 2005 Sep.

—  Wartenberg M. Hoffmann E. Schwindt H. Grunheck F. Petros JA. Arnold JR. Hescheler J. Sauer H. Reactive oxygen species-linked regulation of the multidrug resistance transporter P-glycoprotein in Nox-1 overexpressing prostate tumor spheroids.  FEBS Letters. 579(20):4541-4549, 2005 Aug 15.

—  Phan J, Moffitt R, Dale J, Petros JA, Young A, Wang M.  Improvement of SVM algorithm for microarray analysis using intelligent parameter selection.  Annual international Conference of iEEE Engineering in Medicine and Biology Science. 5: 4838-4841, 2005.

—  Young A, Amin M, Petros JA, Natan M, Nie S, Wang M.  Nanomolecular histopathology for renal tumor classification.  Annual international Conference of iEEE Engineering in Medicine and Biology Science. 1: 723-726, 2005.

—  Wajchman HJ. Pierce CW. Varma VA. Issa MM. Petros JA. Dombrowski KE. Ex vivo expansion of CD8+CD56+ and CD8+CD56- natural killer T cells specific for MUC1 mucin. Cancer Research. 64(3):1171-80, 2004.

—  Wang R. Xu J. Saramaki O. Visakorpi T. Sutherland WM. Zhou J. Sen B. Lim SD. Mabjeesh N. Amin M. Dong JT. Petros JA. Nelson PS. Marshall FF. Zhau HE. Chung LW. PrLZ, a novel prostate-specific and androgen-responsive gene of the TPD52 family, amplified in chromosome 8q21.1 and overexpressed in human prostate cancer. Cancer Research. 64(5):1589-94, 2004 Mar 1.

—  Issa MM. Young MR. Bullock AR. Bouet R. Petros JA.  Dilutional hyponatremia of TURP syndrome: a historical event in the 21st century. Urology. 64(2):298-301, 2004 Aug.

—  Zhou W. Goodman M. Lyles RH. Lim SD. Williams TY. Rusthoven KE. Mandel JS. Amin MB. Petros JA. Surgical margin and gleason score as predictors of postoperative recurrence in prostate cancer with or without chromosome 8p allelic imbalance. Prostate. 61(1):81-91, 2004 Sep 15.

—  Issa MM. Krishnan A. Bouet R. Young MR. Hood N. Petros JA. The fate of the medically castrated testis: expectation versus reality. Journal of Urology. 172(3):1042-4, 2004 Sep.

—  Issa MM. Hsiao K. Bassel YS. Bouet R. Young MR. Petros JA. Spermatic cord anesthesia block for scrotal procedures in outpatient clinic setting.  Journal of Urology. 172(6 Pt 1):2358-61, 2004 Dec.

—  Young AN, de Oliveira Salles PG, Lim SD, Cohen C, Petros JA, Marshall FF, Neish AS, Amin MB.  Beta defensin-1, parvalbumin, and vimentin; a panel of diagnostic immunohistochemical markers for renal tumors derived from gene expression profiling studies using cDNA microarrays.  Am J Surg Path 27(2): 199-205, 2003.

—  Donald CD, Sun CQ, Lim SD, Macoska J, Cohen C, Amin MB, Young AN, Ganz TA, Marshall FF, Petros JA.  Cancer-specific loss of beta-defensin 1 in renal and prostatic carcinomas.  Laboratory Investigation, 83:501-505, 2003.

—  Aldridge BA, Lim SD, Baumann AK, Hosseini S, Buck W, Almekinder TL, Sun CQ, Petros JA.  Automated sequencing of complete mitochondrial genomes from laser-capture microdissected samples.  BioTechniques 35: 606-612, 2003.

—  Arbiser  JL, Petros JA, Klafter R, Govindajaran, B, McLaughlin ER, Brown LF, Cohen C, Moses M, Kilroy S,  Arnold RS, Lambeth JD. Reactive oxygen generated by Nox1 triggers the angiogenic switch. Proceedings of the National Academy of Sciences USA 99(2): 715-720, 2002

—  Lendvay TS. Tandon S. Lumsden AB. Petros JA. Issa MM. Pulsatile mass in the scrotum in a man with the Leriche syndrome. Journal of Urology. 167(1):257-8, 2002.

—  Seabury CA, Calenoff E, Ditlow C, Bux S, Clarke H, Issa M, Marshall F, Petros JA.  Evaluation of a new serum testing method for detection of prostate cancer.  Journal of Urology 168(1):93-9, 2002

—  O’Keefe SC, Marshall FF, Issa MM, Harmon MP, Petros JA. Thrombocytosis is associated with significant increase in cancer-specific death rate following radical nephrectomy.  Journal of Urology. 168(1):93-9, 2002

—  Canatella PJ. Karr JF. Petros JA. Prausnitz MR. Quantitative study of electroporation-mediated molecular uptake and cell viability. Biophysical Journal. 80(2):755-764, 2001

—  Young AN, Amin MB, Moreno CS, Lim SD, Cohen C, Petros JA, Marshall FF, Neish AS. Expression profiling of renal epithelial neoplasms; A method for tumor classification and discovery of diagnostic molecular markers.  Am J Pathol. 158(5): 1639-1651, 2001.

—  Arnold RS, Shi J, Murad E, Whalen AM, Sun CQ, Polavarapu R, Parthasarathy S, Petros JA, Lambeth JD. Hydrogen peroxide mediates the cell growth and transformation caused by the mitogenic oxidase Nox1. Proceedings of the National Academy of Sciences USA. 98(10): 5550-5555, 2001.

—  Wu GJ, Varma VA, Wu MWH, Wang SW, Qu P, Yang H, Petros JA, Lim SD, Amin MB.  Expression of a human cell adhesion molecule, MUC18 in prostate cancer cell lines and tissues. The Prostate 48:305-315, 2001.

—  Jessie BC, Sun CQ, Irons HR, Marshall FF, Wallace DC, Petros JA. Accumulation of mitochondrial DNA deletions in the malignant prostate of patients of different ages.  Experimental Gerontology. 37: 169-174, 2001.

—  Wu GJ, Wu MW, Wang SW, Liu Z, Qu P, Peng Q, Yang H, Varma VA, Sun QC, Petros JA, Lim SD, Amin MB.  Isolation and characterization of the major form of human MUC18 cDNA gene and correlation of MUC18 over-expression in prostate cancer cell lines and tissues with malignant progression.  Gene 279 (1): 17-31, 2001.

—  Donald CD, Laddu A, Chandham P, Lim SD, Cohen C, Amin M, Gerton GL, Marshall FF, Petros JA.  Expression of Progranulin and the Epithelin/Granulin Precursor Acrogranin Correlates with Neoplastic State in Renal Epithelium. Anticancer Research 21(6A): 3739-3742, 2001.

—  McCoy JL, Rucker R, Petros JA: Cell-mediated immunity to tumor-associated antigens is a better predictor of survival in early stage breast cancer than stage, grade or lymph node status.  Breast Cancer Research and Treatment 60:227-234, 2000.

—  Issa MM. Bux S. Chun T. Petros JA. Labadia AJ. Anastasia K. Miller LE. Marshall FF. A randomized prospective trial of intrarectal lidocaine for pain control during transrectal prostate biopsy: the Emory University experience.  J Urol. 164(2):397-9, 2000 Aug.

—  Symbas NP. Townsend MF. El-Galley R. Keane TE. Graham SD. Petros JA. Poor prognosis associated with thrombocytosis in patients with renal cell carcinoma. BJU International. 86(3):203-7, 2000

—  Jimenez RE. Fischer AH. Petros JA. Amin MB. Glutathione S-transferase pi gene methylation: the search for a molecular marker of prostatic adenocarcinoma. Advances in Anatomic Pathology. 7(6):382-9, 2000 Nov.

—  Norris S, Halkar R, Galt J, Petros JA, Keller J: Bone metastases from poorly differentiated adenocarcinoma of the prostate diagnosed by In-111 ProstaScint (Capromab Pendetide) images with negative results of Tc-99m MDP bone scan and without significant elevation of prostate-specific antigen. Clinical Nuclear Medicine. 24(11):905-7, 1999.

—  Issa MM. Perez-Brayfield M. Petros JA. Anastasia K. Labadia AJ. Miller LE. A prospective study of transperineal prostatic block for transurethral needle ablation for benign prostatic hyperplasia: the Emory University Experience. J  Urol. 162(5):1636-9, 1999

—  Issa MM, Kalish J, Petros JA: Clinical features and management of anterior intraurethral prostatic cyst. Urology 54:923, 1999.

—  Keane TE, El-Galley RES, Sun C, Petros JA, Dillahey D, Gomaa A, Graham Jr SD, McGuire III WP.  Camptothecin Analogues/Cisplatin: An Effective Treatment of Advanced Bladder Cancer in a Preclinical In-Vivo Model System.  J Urol. 160 (1): 252-256, 1998

—  Ye K, Ke Y,  Keshava N,  Kapp JA, Tekmal RR, Petros JA,  Joshi HC.: Opium alkaloid noscapine is an anti-tumor agent that arrests metaphase and induces apoptosis in dividing cells.  Proc. Nat. Acad. Sci. 95(4): 1601-1606, 1998.

—  ElGalley RES, Petros JA, Keane TE, Sanders WH, Clarke HS, Graham Jr  SD: Evaluation of staging lymphadenectomy in localized prostate cancer. Urology. 52(4): 663-667, 1998

—  Shridhar V, Sun QC, Miller OJ, Kalemkerian GP, Petros JA, Smith DI: Loss of heterozygosity on the long arm of human chromosome 7 in sporadic renal cell carcinomas.  Oncogene15(22): 2727-2734, 1997.

—  Shridhar V, Wang L, Rosati R, Paradee W, Shridhar R, Mullins C, Sakr W, Grignon D, Miller OJ, Sun QC, Petros JA, Smith DI: Frequent breakpoints in the region surrounding FRA3B in sporadic renal cell carcinomas.  Oncogene 14:1269-1277, 1997.

—  El-Galley, RES, Smith, E., Cohen, C., Petros JA, Woodard, J., and Galloway, NTM.  Epidermal growth factor (EGF) and EGF receptor in hypospadias.  British Journal of Urology 79:116-119, 1997.

—  Horton, TM, Petros JA, Abdelaziz, H, Shoffner, J, Kaufman, AE, Graham, Jr, SD, Gramlich, T, Wallace, DC: Novel Mitochondrial DNA Deletion Found in a Renal Cell Carcinoma.  Genes Chromosomes and Cancer, 15: 95-101, 1996.

—  Graham, SD Jr.  Napalkov, P Oladele, A, Keane, TE, Petros JA, Clarke, HS, Kassabian, VS,Dillehay, DL,:  Intravesical Suramin in the Prevention of Transitional Cell Carcinoma.  Urology; 45(1): 59-63, 1995.

—  Graham, Jr., SD, Keane, TE, Petros JA, Sanders, WH: Perioperative Hormonal Therapy in Locally Advanced Adenocarcinoma of the Prostate.  Cancer; 75(7): 1969-1971, 1995.

—  El-Galley, RES, Petros JA, Sanders, WH, Keane, TE, Galloway, NTM, Cooner WH, Graham, Jr., SD: Normal Range Prostate-Specific Antigen vs. Age-Specific Prostate-Specific Antigen in Screening Prostate Adenocarcinoma.  Urology ; 46(2):200-204, 1995.

—  Keane, TE, Petros JA, Velimirovich, B, Yue, KT, Graham, Jr, SD:  Methoxypsoralen Phototherapy of Transitional Cell Carcinoma.  Urology; 44(6): 842-846, 1994.

—  Petros JA, Andriole, GL:  Serum PSA after Antiandrogen Therapy.  The Urologic Clinics of North America:20(4)749-756, 1993,

—  Kerbl K, Clayman RV, Petros JA, Chandhoke PS, Gill IS: Staging pelvic Lymphadenectomy for Prostate Cancer: A comparison of laparoscopic and open techniques.  J. Urol., 150: 396-399, 1993.

—  Petros JA, Catalona WJ: Lower incidence of unsuspected lymph node metastases in 521 consecutive patients with clinically localized prostate cancer.  J. Urol. 147:1574-1575, 1992.

—  Yuan JJJ, Coplen DE, Petros JA, Figenshan RS, Ratliff TL, Smith DS, Catalona WJ:  Effects of rectal examination, prostatic massage, ultrasonography and needle biopsy on serum prostate specific antigen levels.  J. Urol., 147:810-814, 1992.

—  Catalona WJ, Smith DS, Ratliff, TL, Dodds KM, Coplen DE, Juan JJJ, Petros JA, Andriole GL:  Measurement of Prostate-specific antigen in serum as a screening test for prostate cancer.  N. Engl. J. Med., 324(17): 1156-1161, 1991.

—  Petros JA, Catalona WJ:  Antegrade approach to radical retropubic prostatectomy in patients with difficult apical dissection.  J. Urol., 145(5):994-997; 1991.

—  Petros JA, Andriole GL, Middletown WD, Picus DA: Correlation of testicular color Doppler ultrasonography, physical examination and venography in the detection of left varicoceles in men with infertility.  J. Urol., 145(4): 785-788, 1991.